Roche (RHHBY) Holding has paused some shipments of Elevidys following a similar action by the biotechnology company that developed the treatment, Naomi Kresge of Bloomberg reports. Roche said the move applies to new orders in countries outside of the U.S. that base their approvals on the decision of the FDA. Roche also said the pause is voluntary and temporary, citing an emailed statement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- AstraZeneca (AZN) Commits to $50B U.S. Investment as Tariff Threat Looms
- Roche announces ALIENTO trial meets, ARNASA study misses primary endpoint
- Genetech: STARGLO data does not provide sufficient evidence for DLBCL indication
- Trump says drug tariffs probable by August 1, semis coming soon, Bloomberg says
- FDA willing to trade faster drug reviews for lower prices, Bloomberg reports